Trinity Biotech, FDA Clearance of TRIstat Point-of-Care HbA1c Test

November 29th, 2007 - Trinity Biotech plc (NASDAQ: TRIB) a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that the US Food and Drug Administration has given clearance to market the rapid, point-of-care TRIstat™ HbA1c system... [PDF] Trinity Biotech's Press Release -